证券代码：301087 证券简称：可孚医疗 公告编号：2025-038 可孚医疗科技股份有限公司 关于回购注销部分限制性股票通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 可孚医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开 第二届董事会第十四次会议和第二届监事会第十四次会议，审议通过了《关于回 购注销部分限制性股票的议案》。 根据公司《2021 年限制性股票激励计划（草案）》《2021 年限制性股票激 励计划实施考核管理办法》等相关规定，鉴于公司 2024 年度未达到业绩考核目 标，第一类限制性股票第三个限售期对应的 19.50 万股限制性股票不得解除限售， 董事会审议决定回购注销上述 19.50 万股限制性股票。本次回购注销完成后，公 司总股本将由 209,092,000 股减至 208,897,000 股，公司注册资本也相应由 209,092,000 元减少为 208,897,000 元。 公司本次回购注销部分限制性股票将导致注册资本减少，根据《中华人民共 和国公司法》等相关法律法规的规定，公司特此通知债权 ...

Investment Rating - The investment rating for the company is "Buy" [17] Core Views - The company has shown a strong performance in its rehabilitation aids segment, with a significant revenue increase of 42.77% year-on-year [6] - The company is focusing on core product categories and enhancing R&D efficiency, leading to rapid innovation and product launches [7] - The hearing aid business is developing steadily, with a revenue growth of 37.86% year-on-year, indicating potential for becoming a second growth curve for the company [10] Company Overview - The latest closing price is 32.97 yuan, with a total market capitalization of 6.9 billion yuan [4] - The company reported a revenue of 2.983 billion yuan in 2024, a year-on-year increase of 4.53%, and a net profit of 312 million yuan, up 22.60% [5] - The company has a debt-to-asset ratio of 25.2% and a price-to-earnings ratio of 21.55 [4] Financial Performance - The company expects revenues of 3.449 billion yuan, 4.032 billion yuan, and 4.747 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 15.6%, 16.9%, and 17.7% [11] - The projected net profit for 2025, 2026, and 2027 is 389 million yuan, 454 million yuan, and 564 million yuan, with growth rates of 24.9%, 16.7%, and 24.0% respectively [11] - The company has launched over a hundred new products in 2024, enhancing its product portfolio significantly [7]

Investment Rating - The report assigns a "Buy" rating for the stock, indicating an expected relative price increase of over 20% compared to the benchmark index within the next six months [17]. Core Insights - The company, Kefu Medical, reported a revenue of 2.983 billion yuan for 2024, a year-on-year increase of 4.53%, and a net profit attributable to shareholders of 312 million yuan, up 22.60% year-on-year [5]. - The company is focusing on home medical care, with significant growth in rehabilitation aids, which generated 1.104 billion yuan in revenue, a 42.77% increase [6]. - Kefu Medical launched over a hundred new products in 2024, enhancing its product portfolio in the high-end respiratory support field and other medical devices [7]. - The company has established a multi-channel marketing strategy, achieving 1.990 billion yuan in online sales, a growth of 8.94% [8]. - The hearing aid business is developing steadily, with a revenue of 273 million yuan in 2024, reflecting a growth of 37.86% [10]. - Revenue projections for 2025-2027 are 3.449 billion yuan, 4.032 billion yuan, and 4.747 billion yuan, with corresponding net profits of 389 million yuan, 454 million yuan, and 564 million yuan [11]. Financial Summary - As of the latest report, the company's total market capitalization is 6.9 billion yuan, with a price-to-earnings ratio of 21.55 [4]. - The company’s asset-liability ratio stands at 25.2%, indicating a solid financial position [4]. - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 1.86 yuan, 2.17 yuan, and 2.70 yuan respectively [11].

Group 1: Company Performance - The company achieved a revenue of 2.983 billion CNY in 2024, representing a year-on-year growth of 4.53% [7] - The net profit attributable to shareholders was 312 million CNY, with a year-on-year increase of 22.60% [7] - The net profit excluding non-recurring gains and losses was 275 million CNY, showing a growth of 36.74% [7] - The net cash flow from operating activities reached 663 million CNY, up by 68.45% [7] Group 2: Market and Product Development - The company has established three research institutes focusing on medical electronics, biomedicine, and respiratory support, enhancing its R&D capabilities [2] - The self-developed ventilator has received high consumer recognition, with plans to launch a new generation of products [3] - The hearing aid segment reported a revenue of 273 million CNY in 2024, a growth of 37.86%, despite a loss of 43.25 million CNY due to new store performance [4] Group 3: Strategic Initiatives - The company aims for high-quality, sustainable development through diversified marketing strategies during promotional events [5] - Future dividend policies will focus on stable returns to shareholders while ensuring sustainable company growth [6] - The company is leveraging the "Healthy China" strategy and the aging population trend to drive demand for home medical devices [8] Group 4: Industry Outlook - The medical device industry is expected to grow due to increased health awareness and technological advancements [9] - Companies with strong R&D and operational capabilities are likely to maintain competitiveness, while those with product homogeneity face challenges [9] - The company plans to enhance its core product innovation and expand its international market presence [9]

Core Viewpoint - The event "Intelligent Rehabilitation Aids and Public Welfare Integration Development Forum" was held in Changsha, marking the establishment of the Kefu Medical Public Welfare Foundation, focusing on the integration of rehabilitation technology and public welfare initiatives [1][3]. Group 1: Establishment and Projects - The Kefu Public Welfare Foundation was officially established and announced three major public welfare projects, including the "Hearing Health Care for Retired Veterans" which will donate 1,100 hearing aids [3]. - The "Friendly Hunan: Kefu Love" project aims to support the construction of barrier-free environments in Hunan Province [3]. - The "Youth Spine Health Protection Plan" is expected to benefit 10,000 primary and secondary school students in Hunan, addressing spine health issues [3]. Group 2: Technological Integration and Development - Kefu Medical emphasizes the deep integration of technological innovation and public welfare practices, committing to increase investment in research and public welfare to make rehabilitation technology more accessible [3][6]. - Experts at the forum discussed the importance of integrating technology innovation with public welfare to address health accessibility issues [5]. Group 3: Achievements and Future Plans - Since its establishment in 2022, the Kefu Public Welfare Foundation has made significant contributions in hearing health, education assistance, and rural revitalization, helping 6,496 hearing-impaired children and elderly regain their hearing [5]. - The foundation plans to leverage Kefu's technological advantages in rehabilitation aids and hearing technology to provide smarter hearing devices and customized functional aids for veterans [6].

Core Insights - The aging population, scarcity of grassroots medical resources, and uneven distribution of quality medical resources are driving the rapid integration and application of AI technology in the healthcare sector [2] - AI medical technology is expected to reconstruct the medical value chain, creating a new model for equitable access to medical resources [5] - The domestic AI medical market is projected to reach 159.8 billion yuan by 2028, with a compound annual growth rate of 10.5% from 2022 to 2028 [7] Industry Overview - The aging population in China is expected to reach 310 million by the end of 2024, accounting for 22% of the total population, and is projected to exceed 400 million by 2035, surpassing 30% [2] - Grassroots medical institutions account for 94.9% of all medical institutions in China but only handle 51.8% of the total medical services, indicating a mismatch in resource utilization and service quality [2] - AI technology is being rapidly integrated across various medical processes, including imaging diagnosis, surgical assistance, drug development, and intelligent management [2] AI Medical Technology - AI medical technology enhances the quality and efficiency of healthcare services by providing intelligent management and optimization of medical processes [3] - AI medical devices can be categorized into two types: those that include hardware (e.g., diagnostic analysis systems, robots) and those that operate as standalone software [3] - The advantages of AI in healthcare include high efficiency, accuracy, and low misdiagnosis rates, which can significantly improve diagnostic processes and treatment timelines [4] Market Potential - The AI medical market is expanding rapidly, with significant applications in drug and vaccine development, medical imaging analysis, smart hospital management, and genomics research [7] - AI applications in in-vitro diagnostics are expected to grow at a compound annual growth rate of 26.1% by 2028 [17] Company Profiles - Mindray Medical (300760) has a comprehensive product line in life information and support, in vitro diagnostics, and medical imaging, with a projected revenue of 36.725 billion yuan in 2024, a 5.14% increase year-on-year [10] - United Imaging (688271) focuses on medical imaging equipment and has been investing in AI since 2017, with a projected revenue of 10.3 billion yuan in 2024, a 9.73% decrease year-on-year [14] - BGI Genomics (300676) specializes in genomic testing services and is expected to generate 3.867 billion yuan in revenue in 2024, an 11.10% decrease year-on-year [19] - Yuyue Medical (002223) is a leading provider of medical devices, with a projected revenue of 7.566 billion yuan in 2024, a 5.09% decrease year-on-year [23] - Kefu Medical (301087) focuses on home medical devices and is expected to achieve 2.983 billion yuan in revenue in 2024, a 4.53% increase year-on-year [25]

Group 1 - The core business of the company is the research, production, sales, and service of medical devices, with a wide range of products including blood glucose systems, blood pressure monitors, and various medical supplies [2] - As of the first quarter of 2025, the company reported a revenue of 738 million yuan, a year-on-year decrease of 8.59%, and a net profit of 91.43 million yuan, down 9.68%, with a gross profit margin of 52.17% [2] - The company has received several honors, including being recognized as a potential brand in the Chinese drug retail market for 2023-2024 and as a leading brand for assistive devices in Hunan Province [2] Group 2 - The company's current price-to-earnings (PE) ratio is 22.92, significantly lower than the industry average of 49.40 and the industry median of 36.13, ranking it 50th in the industry [1][3] - The total market capitalization of the company is 6.921 billion yuan [1] - As of the first quarter of 2025, 17 institutions hold shares in the company, with a total holding of 27.4022 million shares valued at 938 million yuan [1]

老铁们，帮主盯着盘面直拍大腿——今天A股这出戏太刺激了！三大指数集体玩起高台跳水，创业板半天就栽了1.35%，3600只股票绿得发慌。但你们猜怎 么着？美容、港口、农业这几个板块愣是杀出重围，上演逆袭剧本！ 港口航运的逆袭密码 中日韩自贸区谈判重启的消息，让沿海港口集体嗨了。连云港、宁波海运涨停不是偶然——三国贸易量每增10%，港口吞吐量就能涨15%。但老铁们注意 了，这波行情有"政策预期"加持，等具体协议落地可能利好出尽，现在追高容易被挂旗杆。 农业股竟成避风港？ 中央一号文件提到的"农业新质生产力"，让秋乐种业这类企业突然吃香。数字农业管理系统能精准控制施肥量，节水30%的同时增产15%，这才是资金追捧 的硬逻辑。但农业股波动大得像坐过山车，没金刚钻别揽瓷器活。 先说这冰火两重天 开盘半小时就看出端倪：AI智能体、液冷服务器这些科技小鲜肉集体扑街，军工老大哥也蔫了吧唧。反观美容护理板块，芭薇股份直接30cm涨停，连云 港、川宁生物这些冷门股突然变显眼包。这行情就像火锅局——辣锅沸腾（消费股），清汤寡水（科技股），吃得人冰火两重天。 美容股为啥突然吃香？ 山东卫健委刚甩出王炸政策——允许医美机构搞光电注射项 ...

Investment Rating - The report maintains an investment rating of "Outperform the Market" for the medical device industry [2]. Core Insights - The report emphasizes that AI in healthcare is restructuring diagnostic and treatment processes, creating investment opportunities driven by efficiency and market growth. The global healthcare sector faces challenges such as aging populations and uneven distribution of medical resources, which AI can address by optimizing the healthcare value chain and promoting equitable access to medical resources [5][6]. Summary by Sections 1. AI Healthcare Development Environment - The domestic AI healthcare development environment is mature, supported by data resources and services that enhance algorithm accuracy and generalization [11]. - AI technology is breaking the uneven distribution of medical resources, addressing the growing demand for healthcare services due to an aging population [18][19]. 2. AI Medical Imaging - AI medical imaging is the most mature application of AI in healthcare, with a complete ecosystem covering various imaging modalities such as CT, MRI, and X-ray. The market for AI medical imaging in China is projected to reach 6.17 billion yuan by 2025 [5][39]. - Companies like Mindray and United Imaging are leveraging hardware advantages to build "device + AI" ecosystems, while pure AI companies focus on lesion recognition and cross-disease generalization capabilities [5][39]. 3. AI In Vitro Diagnostics - The AI in vitro diagnostics market is rapidly growing, with applications in hematology, microbiology, and pathology. Companies like BGI and Anbiping are innovating with AI-driven solutions to enhance diagnostic efficiency [5][6]. 4. AI Wearable Devices - AI wearable devices are transforming health management by providing real-time monitoring and data analysis, becoming essential for chronic disease management. The market for smart wearable devices in China is expected to exceed 15 billion yuan in 2023 and reach 33 billion yuan by 2026, with a compound annual growth rate of 18.1% [6]. 5. Investment Recommendations - The report suggests that the industry is poised for multidimensional development, transitioning from scale expansion to higher-level growth. It highlights long-term investment opportunities in leading companies like Mindray, United Imaging, Yuyue Medical, and Kefu Medical, which are early adopters of AI healthcare solutions [6].

粮价稳步上行，种植周期崛起 — — 种 植 业 动态跟踪报告 分析师：李晓渊 执业证书编号：S0930523100002 联系人：于明正 2025年5月12日 证券研究报告 核心结论 粮价开启稳步上行，长期增量扩面趋势有望延续。 全球市场：24/25种植季，由于海外天气影响，全球玉米减产，叠加大豆价格低迷影响，新季全球玉米种植面积和产量预测向上，全球供需 预计仍将偏紧平衡。 国内市场：（1）中短期玉米库存压力缓解驱动价格回暖，种植利润修复；（2）25年Q1粮食进口大幅缩量，进口调控保障国内粮价合理、 稳定，利好长期种植意愿和种植面积扩张；（3）替代品方面，小麦供需同样趋紧，饲用替代空间有限，玉米价格仍具备一定上行空间； （4）下游养殖利润回暖，短期需求周期性改善。长期视角下，国内饲用玉米需求量持续增长，需要种植面积和单产水平提升保障主粮安全。 投资建议：把握三条主线，（1）种植：玉米、小麦等主粮价格稳步上行直接利好大种植标的，主营业务利润有望逐步改善，建议关注北大 荒、苏垦农发等；（2）种子：受益于种植景气回升，种业需求基本面逐步改善，关注具备品种优势和强推广能力的企业，建议关注隆平高 科、荃银高科、秋乐种业 ...